SNPX (SNPX)
Tradr 2X Long SNPS Daily ETF
BATS:SNPXHealthcare · Biotechnology
Mkt Cap-
Float1.38M
O/S-
Inst Own-
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$29.08B
Total Assets$25.84B
Free Cash Flow-$6.4B
Debt & Equity
Equity 100%
Total Debt$0
Total Equity$21.05B
Shares Outstanding
Short Interest
Split History2 splits · 2 reverse
- 1:25Reverse splitApr 5, 202425 shares → 1
- 1:4Reverse splitMay 19, 20214 shares → 1
Balance Sheet Details
Assets$25.84B
Liabilities$3.94B
Accounts Receivable$0
Accounts Payable$1.18B
Inventory$0
PP&E (Net)$9.31M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Revenue | $0 |
| YoY Growth | - |
| Cost of Revenue | $0 |
| Gross Profit | $0 |
| Gross Margin | - |
| Research and Development | $322.23M |
| Selling, General, and Administrative | $9.02B |
| Other | $0 |
| Total Operating Expenses | $9.35B |
| Operating Income (EBIT) | -$9.05B |
| Operating Margin | - |
| Interest Expense | $0 |
| Interest Income | $442.91M |
| Other Income (Expense) | -$19.69B |
| Income Before Tax (EBT) | -$28.74B |
| Income Tax Expense | $338.36M |
| Net Income | -$29.08B |
| Net Income Margin | - |
| Supplementary Data | |
| EPS | -8.81 |
| Diluted EPS | -8.81 |
| Weighted Average OS | 3.30M |
| EBITDA | $4K |
| EBITDA Margin | - |
Balance Sheet
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Assets | |
| Current Assets | |
| Cash and Cash Equivalents | $5.5B |
| Short-Term Investments | $0 |
| Cash and Short-Term Investments | $5.5B |
| Accounts Receivable | $0 |
| Inventory | $0 |
| Other Current Assets | $19.88B |
| Total Current Assets | $25.38B |
| Long-Term Assets | |
| Property, Plant & Equipment Net | $9.31M |
| Goodwill | $0 |
| Intangible Assets | $0 |
| Long-Term Investments | $446.95M |
| Deferred Tax Assets | $0 |
| Other Long-Term Assets | $0 |
| Total Long-Term Assets | $456.26M |
| Other Assets | $0 |
| Total Assets | $25.84B |
| Liabilities | |
| Current Liabilities | |
| Accounts Payable | $1.18B |
| Short-Term Debt | $0 |
| Current Income Tax Payable | $0 |
| Current Unearned Revenue | $0 |
| Other Current Liabilities | $1.81B |
| Total Current Liabilities | $1.81B |
| Long-Term Liabilities | |
| Long-Term Debt | $0 |
| Long-Term Unearned Revenue | $0 |
| Long-Term Deferred Tax Liabilities | $0 |
| Other Long-Term Liabilities | $2.12B |
| Total Long-Term Liabilities | $2.12B |
| Other Liabilities | $0 |
| Total Liabilities | $3.94B |
| Stockholders' Equity | |
| Preferred Stock | $0 |
| Common Stock | $746K |
| Retained Earnings | -$76.2B |
| Comprehensive Income & Other | $5.7M |
| Other Stockholders' Equity | $97.25B |
| Total Equity | $21.05B |
| Minority Interest | $0 |
| Total Liabilities and Equity | $24.99B |
| Supplementary Data | |
| Total Debt | $0 |
| Net Debt | -$5.5B |
Cash Flow Statement
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Operating Activities | |
| Net Income | -$28.74M |
| Depreciation & Amortization | $4K |
| Deferred Income Tax | $0 |
| Stock-Based Compensation | $1.39M |
| Changes in Working Capital: | |
| Accounts Receivable | $0 |
| Inventory | $0 |
| Accounts Payable | $858K |
| Other Working Capital | $0 |
| Total Working Capital Change | $0 |
| Other Non-Cash Items | -$6.37B |
| Net Cash from Operating | -$6.4B |
| Investing Activities | |
| Capital Expenditures | $0 |
| Acquisitions | $0 |
| Purchases of Investments | -$750M |
| Sales of Investments | $0 |
| Other Investing Activities | -$28.14B |
| Net Cash from Investing | -$28.89B |
| Financing Activities | |
| Debt Repaid | - |
| Common Stock Issuance | $758.69M |
| Common Stock Repurchases | $0 |
| Dividends Paid | $0 |
| Other Financing Activities | $23.13B |
| Net Cash from Financing | $23.13B |
| Forex Effect | $0 |
| Net Change in Cash | -$12.16B |
| Supplementary Data | |
| Operating Cash Flow | -$6.4B |
| Capital Expenditure | $0 |
| Free Cash Flow | -$6.4B |
| Cash at Beginning | $17.66B |
| Cash at End | $5.5B |